JP2015519383A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015519383A5 JP2015519383A5 JP2015516609A JP2015516609A JP2015519383A5 JP 2015519383 A5 JP2015519383 A5 JP 2015519383A5 JP 2015516609 A JP2015516609 A JP 2015516609A JP 2015516609 A JP2015516609 A JP 2015516609A JP 2015519383 A5 JP2015519383 A5 JP 2015519383A5
- Authority
- JP
- Japan
- Prior art keywords
- sphingomyelin
- mixture
- empty liposomes
- cholesterol
- beauty
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002502 liposome Substances 0.000 claims description 68
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 62
- 239000000203 mixture Substances 0.000 claims description 58
- 150000002632 lipids Chemical class 0.000 claims description 32
- 235000012000 cholesterol Nutrition 0.000 claims description 31
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 24
- 125000004432 carbon atom Chemical group C* 0.000 claims description 12
- 208000035143 Bacterial infection Diseases 0.000 claims description 10
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 10
- -1 sphingomyelin Chemical compound 0.000 claims description 10
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims description 9
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 claims description 9
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims description 9
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims description 9
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 claims description 9
- 229940106189 ceramide Drugs 0.000 claims description 9
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 claims description 9
- 150000001982 diacylglycerols Chemical class 0.000 claims description 9
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 claims description 9
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims description 9
- 150000003904 phospholipids Chemical class 0.000 claims description 9
- 229920006395 saturated elastomer Polymers 0.000 claims description 9
- 235000003441 saturated fatty acids Nutrition 0.000 claims description 9
- 150000004671 saturated fatty acids Chemical class 0.000 claims description 9
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims description 9
- 150000004670 unsaturated fatty acids Chemical class 0.000 claims description 9
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 claims description 7
- 230000002265 prevention Effects 0.000 claims description 4
- 230000003796 beauty Effects 0.000 claims 24
- 239000008194 pharmaceutical composition Substances 0.000 claims 21
- 150000001875 compounds Chemical class 0.000 claims 4
- 239000000232 Lipid Bilayer Substances 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000013554 lipid monolayer Substances 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 208000031729 Bacteremia Diseases 0.000 claims 1
- 241000894006 Bacteria Species 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 201000009906 Meningitis Diseases 0.000 claims 1
- 206010057190 Respiratory tract infections Diseases 0.000 claims 1
- 229940035676 analgesics Drugs 0.000 claims 1
- 239000000730 antalgic agent Substances 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 230000001147 anti-toxic effect Effects 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims 1
- 229960001231 choline Drugs 0.000 claims 1
- 238000002651 drug therapy Methods 0.000 claims 1
- 231100000444 skin lesion Toxicity 0.000 claims 1
- 206010040882 skin lesion Diseases 0.000 claims 1
- 239000005526 vasoconstrictor agent Substances 0.000 claims 1
- 229930182558 Sterol Natural products 0.000 description 3
- 150000002313 glycerolipids Chemical class 0.000 description 3
- 150000003408 sphingolipids Chemical class 0.000 description 3
- 150000003432 sterols Chemical class 0.000 description 3
- 235000003702 sterols Nutrition 0.000 description 3
- 150000008103 phosphatidic acids Chemical class 0.000 description 2
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12171924.9 | 2012-06-14 | ||
| EP12171924 | 2012-06-14 | ||
| EP13153039.6 | 2013-01-29 | ||
| EP13153039 | 2013-01-29 | ||
| PCT/EP2013/062207 WO2013186286A1 (en) | 2012-06-14 | 2013-06-13 | Tailored liposomes for the treatment of bacterial infections |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018145681A Division JP6656321B2 (ja) | 2012-06-14 | 2018-08-02 | 細菌感染症の処置のためのテイラーメードされたリポソーム |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015519383A JP2015519383A (ja) | 2015-07-09 |
| JP2015519383A5 true JP2015519383A5 (enExample) | 2017-11-16 |
| JP6382801B2 JP6382801B2 (ja) | 2018-08-29 |
Family
ID=48703423
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015516609A Active JP6382801B2 (ja) | 2012-06-14 | 2013-06-13 | 細菌感染症の処置のためのテイラーメードされたリポソーム |
| JP2018145681A Active JP6656321B2 (ja) | 2012-06-14 | 2018-08-02 | 細菌感染症の処置のためのテイラーメードされたリポソーム |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018145681A Active JP6656321B2 (ja) | 2012-06-14 | 2018-08-02 | 細菌感染症の処置のためのテイラーメードされたリポソーム |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US10744089B2 (enExample) |
| EP (2) | EP3782606A1 (enExample) |
| JP (2) | JP6382801B2 (enExample) |
| CN (2) | CN104602672B (enExample) |
| AU (2) | AU2013276565B2 (enExample) |
| BR (1) | BR112014031278B1 (enExample) |
| CA (1) | CA2875470C (enExample) |
| CY (1) | CY1123337T1 (enExample) |
| DK (1) | DK2861214T3 (enExample) |
| ES (1) | ES2821502T3 (enExample) |
| HR (1) | HRP20201761T1 (enExample) |
| HU (1) | HUE051761T2 (enExample) |
| LT (1) | LT2861214T (enExample) |
| PL (1) | PL2861214T3 (enExample) |
| RS (1) | RS60951B1 (enExample) |
| RU (1) | RU2672106C2 (enExample) |
| SI (1) | SI2861214T1 (enExample) |
| SM (1) | SMT202000584T1 (enExample) |
| WO (1) | WO2013186286A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104602672B (zh) * | 2012-06-14 | 2018-12-25 | 伯尔尼大学 | 用于治疗细菌感染的定制脂质体 |
| US20170000875A1 (en) | 2013-12-02 | 2017-01-05 | Arytha Biosciences, Llc | Toxoid preparation and uses thereof |
| US10739353B2 (en) * | 2014-12-31 | 2020-08-11 | Signpath Pharma, Inc. | Suppression of cytokine release and cytokine storm |
| WO2017115358A1 (en) | 2015-12-28 | 2017-07-06 | Mb Biotech Ltd. | Liposomes for treatment of an autoimmune disease |
| EP3440187A1 (en) | 2016-04-07 | 2019-02-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Francisella lipids as broad anti-inflammatory therapeutics and associated methods of use |
| LT3471732T (lt) | 2016-06-16 | 2020-09-10 | Combioxin Sa | Liposomos, skirtos virusinių infekcijų gydymui |
| CN116549393A (zh) * | 2017-03-02 | 2023-08-08 | 康柏辛股份有限公司 | 抑制生物膜形成的脂质体 |
| US11344497B1 (en) | 2017-12-08 | 2022-05-31 | Quicksilver Scientific, Inc. | Mitochondrial performance enhancement nanoemulsion |
| PT3781172T (pt) | 2018-04-17 | 2023-10-11 | Combioxin Sa | Tratamento da pneumonia |
| RS66040B1 (sr) * | 2018-04-20 | 2024-11-29 | Combioxin Sa | Lečenje hipotenzije sa sepsom ili septičkim šokom |
| CN111214439B (zh) * | 2018-11-23 | 2023-02-10 | 复旦大学 | 一种具有细菌成孔毒素吸附性能的纳米药物系统及其用途 |
| EP4093458A4 (en) | 2020-01-20 | 2024-01-17 | Arytha Biosciences LLC | Devices containing cellular membrane and uses thereof |
| WO2022026170A1 (en) * | 2020-07-31 | 2022-02-03 | Signpath Pharma, Inc. | Suppression of cytokine release and cytokine storm |
| CN115054577B (zh) * | 2022-05-17 | 2024-06-21 | 温州医科大学附属第二医院（温州医科大学附属育英儿童医院） | 纳米解毒剂及其在中和mrsa穿孔毒素的应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU6428890A (en) * | 1989-09-12 | 1991-04-18 | Regents Of The University Of California, The | Therapeutic peptides and proteins |
| NL9000207A (enExample) * | 1990-01-29 | 1991-08-16 | Duphar Int Res | |
| WO1993004672A1 (en) * | 1991-09-11 | 1993-03-18 | Pitman-Moore, Inc. | Method for enhancing the immune system in a host employing liposome-encapsulated polypeptides |
| US5741516A (en) * | 1994-06-20 | 1998-04-21 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
| US5543152A (en) * | 1994-06-20 | 1996-08-06 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
| US6726925B1 (en) * | 1998-06-18 | 2004-04-27 | Duke University | Temperature-sensitive liposomal formulation |
| US8110217B2 (en) * | 2001-08-13 | 2012-02-07 | University Of Pittsburgh | Sphingomyelin liposomes for the treatment of hyperactive bladder disorders |
| ES2387886T3 (es) * | 2001-11-13 | 2012-10-03 | Celator Pharmaceuticals, Inc. | Composiciones que transportan lípidos con una mejor estabilidad sanguínea |
| CA2368656A1 (en) * | 2002-01-21 | 2003-07-21 | Vasogen Ireland Limited | Receptor-ligand pairing for anti-inflammatory response |
| EP1531828A4 (en) * | 2002-05-23 | 2005-11-02 | Activbiotics Inc | METHODS OF TREATING BACTERIAL INFECTIONS AND ASSOCIATED DISEASES |
| CA2506749A1 (en) * | 2002-11-26 | 2004-06-10 | Gilead Sciences, Inc. | Method of drug loading in liposomes by gradient |
| US20060198882A1 (en) * | 2003-03-21 | 2006-09-07 | Yechezkel Barenholz | Stable liposomes or micelles comprising a sphinolipid and a peg-lipopolymer |
| JP4990786B2 (ja) * | 2004-11-05 | 2012-08-01 | イネックス ファーマシューティカルズ コーポレイション | 薬物リポソーム製剤を安定化するための組成物および方法 |
| CN1939340A (zh) * | 2005-09-29 | 2007-04-04 | 中国人民解放军军事医学科学院毒物药物研究所 | 脂质体制剂 |
| WO2008039989A2 (en) * | 2006-09-28 | 2008-04-03 | Transave, Inc. | Formulations of dnase and methods of use thereof |
| CA2669355C (en) * | 2006-11-06 | 2012-10-30 | Jina Pharmaceuticals, Inc. | Guggulphospholipid methods and compositions |
| CN1994279A (zh) * | 2006-12-31 | 2007-07-11 | 西安力邦医药科技有限责任公司 | 注射用盐酸伊立替康脂质体的制备方法 |
| CN101623262B (zh) * | 2009-08-24 | 2011-02-02 | 海南美大制药有限公司 | 一种五水头孢唑啉钠前体脂质体制剂 |
| CN103153283B (zh) * | 2010-06-19 | 2017-05-17 | 健康科学西部大学 | Peg化脂质体包封的糖肽抗生素的新制剂 |
| SG187770A1 (en) * | 2010-08-12 | 2013-03-28 | Univ Nanyang Tech | A liposomal formulation for ocular drug delivery |
| CN102327220B (zh) * | 2011-07-14 | 2012-09-26 | 海南灵康制药有限公司 | 一种氯雷他定脂质体固体制剂 |
| CN104602672B (zh) * | 2012-06-14 | 2018-12-25 | 伯尔尼大学 | 用于治疗细菌感染的定制脂质体 |
-
2013
- 2013-06-13 CN CN201380031384.7A patent/CN104602672B/zh active Active
- 2013-06-13 WO PCT/EP2013/062207 patent/WO2013186286A1/en not_active Ceased
- 2013-06-13 DK DK13732388.7T patent/DK2861214T3/da active
- 2013-06-13 SI SI201331806T patent/SI2861214T1/sl unknown
- 2013-06-13 AU AU2013276565A patent/AU2013276565B2/en active Active
- 2013-06-13 CA CA2875470A patent/CA2875470C/en active Active
- 2013-06-13 LT LTEP13732388.7T patent/LT2861214T/lt unknown
- 2013-06-13 RU RU2014148284A patent/RU2672106C2/ru active
- 2013-06-13 PL PL13732388T patent/PL2861214T3/pl unknown
- 2013-06-13 HU HUE13732388A patent/HUE051761T2/hu unknown
- 2013-06-13 HR HRP20201761TT patent/HRP20201761T1/hr unknown
- 2013-06-13 SM SM20200584T patent/SMT202000584T1/it unknown
- 2013-06-13 US US14/404,985 patent/US10744089B2/en active Active
- 2013-06-13 BR BR112014031278-8A patent/BR112014031278B1/pt active IP Right Grant
- 2013-06-13 RS RS20201252A patent/RS60951B1/sr unknown
- 2013-06-13 EP EP20189368.2A patent/EP3782606A1/en active Pending
- 2013-06-13 ES ES13732388T patent/ES2821502T3/es active Active
- 2013-06-13 JP JP2015516609A patent/JP6382801B2/ja active Active
- 2013-06-13 EP EP13732388.7A patent/EP2861214B1/en active Active
- 2013-06-13 CN CN201811433069.8A patent/CN109549925B/zh active Active
-
2018
- 2018-08-02 JP JP2018145681A patent/JP6656321B2/ja active Active
-
2019
- 2019-03-14 AU AU2019201776A patent/AU2019201776B2/en active Active
-
2020
- 2020-07-09 US US16/924,539 patent/US20200345639A1/en not_active Abandoned
- 2020-09-16 CY CY20201100878T patent/CY1123337T1/el unknown
-
2021
- 2021-11-30 US US17/537,862 patent/US20220087934A1/en not_active Abandoned
-
2022
- 2022-09-30 US US17/957,402 patent/US20230031648A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015519383A5 (enExample) | ||
| JP2018184470A5 (enExample) | ||
| HRP20201761T1 (hr) | Prilagođeni liposomi za tretman bakterijskih infekcija | |
| JP2015515992A5 (enExample) | ||
| JP6444865B2 (ja) | ダイズホスファチジルセリンで作られたコクリエート | |
| MX2011000932A (es) | Metodos para administrar formulaciones antifungicas topicas para el tratamiento de infecciones fungicas. | |
| AU2010255391B2 (en) | Formulations for the treatment of deep tissue pain | |
| JP2011021026A5 (enExample) | ||
| CA2751412A1 (en) | Methods of reducing the proliferation and viability of microbial agents | |
| JP2017524658A5 (enExample) | ||
| JP2016040277A (ja) | 小胞状の製剤 | |
| RU2014120216A (ru) | Комбинационные липосомальные композиции для лечения рака | |
| HU198836B (en) | Composition suitable for forming liposomes | |
| AU2012214662A1 (en) | Permeation enhancers for topical formulations | |
| BR112014018393A8 (pt) | Composição farmacêutica adequada para liberação ocular de um esteroide e uso da mesma para a fabricação de um medicamento para tratar uma doença oftálmica | |
| JP2021091730A (ja) | 多相組成物 | |
| CN106456545A (zh) | 免疫原性的脂质体制剂 | |
| WO2012109151A1 (en) | Permeation enhancers with liposomes for topical formulations | |
| JP2008528696A5 (enExample) | ||
| JP2015511618A (ja) | 小胞製剤 | |
| JP6991592B2 (ja) | 中枢神経系送達のためのコクリエート化抗真菌化合物及びクリプトコッカス感染症の治療 | |
| FI3954360T3 (fi) | Hiilihydraattien lääkevalmiste terapeuttiseen käyttöön | |
| JP2015516454A (ja) | ベシクル製剤のキットおよび使用 | |
| US20150125407A1 (en) | Vesicular Formulations, Uses and Methods | |
| JP2018517736A5 (enExample) |